These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 19462153

  • 1. The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction.
    Lim SY, Davidson SM, Yellon DM, Smith CC.
    Basic Res Cardiol; 2009 Nov; 104(6):781-92. PubMed ID: 19462153
    [Abstract] [Full Text] [Related]

  • 2. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
    Tam J, Godlewski G, Earley BJ, Zhou L, Jourdan T, Szanda G, Cinar R, Kunos G.
    Am J Physiol Endocrinol Metab; 2014 Feb 15; 306(4):E457-68. PubMed ID: 24381003
    [Abstract] [Full Text] [Related]

  • 3. Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade.
    Crespillo A, Suárez J, Bermúdez-Silva FJ, Rivera P, Vida M, Alonso M, Palomino A, Lucena MA, Serrano A, Pérez-Martín M, Macias M, Fernández-Llébrez P, Rodríguez de Fonseca F.
    Biochem J; 2011 Jan 01; 433(1):175-85. PubMed ID: 20955176
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.
    Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrié P.
    Int J Obes Relat Metab Disord; 2004 Apr 01; 28(4):640-8. PubMed ID: 14770190
    [Abstract] [Full Text] [Related]

  • 8. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.
    Kim SP, Woolcott OO, Hsu IR, Stefanoski D, Harrison LN, Zheng D, Lottati M, Kolka C, Catalano KJ, Chiu JD, Kabir M, Ionut V, Bergman RN, Richey JM.
    Am J Physiol Endocrinol Metab; 2012 May 01; 302(10):E1261-8. PubMed ID: 22374758
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.
    Mukhopadhyay P, Bátkai S, Rajesh M, Czifra N, Harvey-White J, Haskó G, Zsengeller Z, Gerard NP, Liaudet L, Kunos G, Pacher P.
    J Am Coll Cardiol; 2007 Aug 07; 50(6):528-36. PubMed ID: 17678736
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
    Cota D, Sandoval DA, Olivieri M, Prodi E, D'Alessio DA, Woods SC, Seeley RJ, Obici S.
    Obesity (Silver Spring); 2009 Aug 07; 17(8):1641-5. PubMed ID: 19325539
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
    Mastinu A, Pira M, Pani L, Pinna GA, Lazzari P.
    Behav Brain Res; 2012 Oct 01; 234(2):192-204. PubMed ID: 22771813
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile.
    Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, Janiak P, Herbert JM.
    Diabetes Obes Metab; 2005 Jan 01; 7(1):65-72. PubMed ID: 15642077
    [Abstract] [Full Text] [Related]

  • 17. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gαi/o protein inhibitor.
    Porcu A, Melis M, Turecek R, Ullrich C, Mocci I, Bettler B, Gessa GL, Castelli MP.
    Neuropharmacology; 2018 May 01; 133():107-120. PubMed ID: 29407764
    [Abstract] [Full Text] [Related]

  • 18. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
    Zádor F, Lénárt N, Csibrány B, Sántha M, Molnár M, Tuka B, Samavati R, Klivényi P, Vécsei L, Marton A, Vizler C, Nagy GM, Borsodi A, Benyhe S, Páldy E.
    Neuropharmacology; 2015 Feb 01; 89():298-307. PubMed ID: 25446673
    [Abstract] [Full Text] [Related]

  • 19. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes.
    Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M.
    Mol Pharmacol; 2006 Feb 01; 69(2):471-8. PubMed ID: 16282221
    [Abstract] [Full Text] [Related]

  • 20. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN, Joharapurkar AA, Patel V, Kshirsagar SG, Bahekar R, Srivastava BK, Jain MR.
    Can J Physiol Pharmacol; 2014 Dec 01; 92(12):975-83. PubMed ID: 25361428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.